This purposeful conversation in between the serotoninergic and central dopaminergic programs continues to be demonstrated in experiments with haloperidol, a D2 receptor antagonist that attenuates the psychotomimetic results of psilocybin [5].Psilocybin that contains mushrooms: a quickly acquiring biotechnology market in the psychiatry, biomedical a